Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Randomized, Double Blind Treatment Period:~Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features~* Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy~* Progressive disease despite androgen deprivation therapy as defined by rising PSA levels or progressive soft tissue or bony disease~* No prior treatment with cytotoxic chemotherapy~* Asymptomatic or mildly symptomatic from prostate cancer~Exclusion Criteria:~* Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment~* Known or suspected brain metastasis or active leptomeningeal disease~* History of another malignancy within the previous 5 years other than curatively treated non-melanomatous skin cancer~Open-Label Treatment Period:~The following inclusion criteria apply to patients receiving enzalutamide or placebo during double-blind treatment.~Eligible patients must meet all inclusion criteria.~* Received randomized double-blind treatment in PREVAIL;~* Open-label day 1 visit is within 6 months after this amendment is approved and becomes effective at the study site;~* Is willing to maintain androgen deprivation therapy with a gonadotropin-releasing hormone (GnRH) agonist/antagonist or has had a bilateral orchiectomy;~The exclusion criteria apply only to patients starting new treatment with enzalutamide after receiving placebo as randomized treatment. Each patient must not meet any of the following criteria:~* Has taken commercially available enzalutamide (Xtandi);~* Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment~* Known or suspected brain metastasis or active leptomeningeal disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzalutamide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).